{"name":"Wugen, Inc.","slug":"wugen-inc","ticker":"","exchange":"","domain":"","description":"Wugen, Inc. is a biotechnology company focused on developing innovative cell therapies for cancer. The company's pipeline includes several candidates in early clinical stages, targeting various hematological and solid tumors.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Cetuximab - Dose Escalation","genericName":"Cetuximab - Dose Escalation","slug":"cetuximab-dose-escalation","indication":"Other","status":"phase_1"},{"name":"WU-NK-101","genericName":"WU-NK-101","slug":"wu-nk-101","indication":"Other","status":"phase_1"},{"name":"WU-NK-101 - Dose Escalation","genericName":"WU-NK-101 - Dose Escalation","slug":"wu-nk-101-dose-escalation","indication":"Other","status":"phase_1"},{"name":"Cetuximab - Cohort Expansion","genericName":"Cetuximab - Cohort Expansion","slug":"cetuximab-cohort-expansion","indication":"Other","status":"phase_1"},{"name":"WU-CART-007","genericName":"WU-CART-007","slug":"wu-cart-007","indication":"Other","status":"phase_2"},{"name":"WU-NK-101 - Cohort Expansion","genericName":"WU-NK-101 - Cohort Expansion","slug":"wu-nk-101-cohort-expansion","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Cetuximab - Dose Escalation","genericName":"Cetuximab - Dose Escalation","slug":"cetuximab-dose-escalation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"WU-NK-101","genericName":"WU-NK-101","slug":"wu-nk-101","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"WU-NK-101 - Dose Escalation","genericName":"WU-NK-101 - Dose Escalation","slug":"wu-nk-101-dose-escalation","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Cetuximab - Cohort Expansion","genericName":"Cetuximab - Cohort Expansion","slug":"cetuximab-cohort-expansion","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"WU-CART-007","genericName":"WU-CART-007","slug":"wu-cart-007","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"WU-NK-101 - Cohort Expansion","genericName":"WU-NK-101 - Cohort Expansion","slug":"wu-nk-101-cohort-expansion","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOYVE1WmZ6Q1JxWVNyb0tFMDhUWWNURXU3WDBFekJVUUt4eWxMeHdzZzcwVEVpaEtHbVEzXzFmUWNZX05VVEZ4Q29uUlI0ZnRJTERhdG81S3RsRXV0TEd6RWRjUVNWang1dDVhbkZPbVZucWFSQ0pNV0t5S3dIYjVrcE1jdEtyT25wRm5LN1ZjaWNRZW1kRmFoQkNBaldBNlNJMlc0TENCTmFpQmFSZ0pHWjRDMHJjV3FZcmxIb1hvdWpfbGRTM1NNY2p1SWJFRV9kSlcwal9va0ViOHBrS1dCQ0ZUSjY5VGdVU0lj?oc=5","date":"2026-04-02","type":"regulatory","source":"CRISPR Medicine News","summary":"Wugen Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of Soficabtagene Geleucel - CRISPR Medicine News","headline":"Wugen Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Ma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxNMWxVNTZsUVo3bTZVanROSDd4TUhJU0NjeVdZTFEzTXVwT2w1dUlCTWlGU0I5MUJjNUtGU0J5Zno0d2E5emVrRU15ekZ5WEVrWmZTc1EyZm5xQmJOU21VMHQ2OFpwdnlMbExrcjRxZmhYM0Npa3k4ZmJsZkREWm0zRUNuT2ZncnF6OXg5REpFTmlXdWJEUXhLUmtfZ1VoWXA4YlZpazZ3T2pIUDhvZUM0dGI5OTVQVFIyRV96dmFyVVFHd3hkX3RVdV8tUVp3dTh1RVNLeGUyRGlDMWhrRkVxXzVOalhuQm9zUTYtSzVMU0d3Vl9HUC1hZzJPVVc0OXE2QkVfZUZsZ090UXk4VlphdTA0ZVlaUDFKbVVyTUZuVmVMaU1Cc2lYZzViY2xQdXlyTG53RmtZdHVydnc?oc=5","date":"2026-01-21","type":"regulatory","source":"BioSpace","summary":"U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic Lymphoma - BioSpace","headline":"U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPTjJZWi13MXlKbUFKR0FGYWJkMGlfdkxQMHl6WFc2WldPa2JxVkR6N2tKVjRERkItbVdHNzdIN1JQSFhXV2lOaVVIQkU4ZTZ6NnZob1hUc3NqWVpKTmpibnlpY0VTdXE3RGJHd2s5UWdxdWRVT0Z4Q0VRU1ptRy1YVEQ4WGZKaW9pWUN5bHEwdjQ?oc=5","date":"2025-08-27","type":"pipeline","source":"BioPharma Dive","summary":"Startup Wugen raises $115M for ‘off-the-shelf’ CAR-T - BioPharma Dive","headline":"Startup Wugen raises $115M for ‘off-the-shelf’ CAR-T","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-06","type":"regulatory","source":"Business Wire","summary":"CAR-T Cell Therapy Market Research 2024-2025: Size, Forecasts, Trials, and Trends - Approved CAR-T Therapies and Late-stage Clinical Trials that Could Reach Commercialization Soon - ResearchAndMarkets","headline":"CAR-T Cell Therapy Market Research 2024-2025: Size, Forecasts, Trials, and Trends - Approved CAR-T Therapies and Late-st","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5ydmhpb1lZUmFPQ3hVNFc1VGlNbkpRM0NaVXJWa21WcUV5QVFTaFVOU2x2SXc2bnZHXzFnLUN1bDVFcjA5NDc0a1RIeV9nbFNmUjRROGwwOHlhLTc3b2c?oc=5","date":"2024-06-30","type":"pipeline","source":"Exploding Topics","summary":"44 Fast-Growing Biotech Companies & Startups (2024) - Exploding Topics","headline":"44 Fast-Growing Biotech Companies & Startups (2024)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxQSF9TYTYtNllWVm1wZnZxRkgwVHhOV1BTOUFxcDgzcHFYLWptNlJVdWVJSVFhbC0zT09fc05yeGxIb1A1d29scXZnaFp6ZEhGNW94SVoxSU9GU3BGOVhxN2FKdzR4UUFoY0FjVzJENVQwci0zZEMydnN6Q2lURktTdXYydFdBWmszWEFVMlZ2Z1JIZW5CM1lFSDdFU2VqZnU3MU56Tkd3bHJpeWptRi1kNFB5QnNoZlJ5dHZQRlRHdVA2RDVva08tcVhVeWlZanBlYVIxN3kyaTVuYnJ5SDY5RXdGdEZ2ZlkyYlpReXVZc1FTZDJQTzBrV3dWaWJERmZVRnJKWmdzOXdXZ0FD?oc=5","date":"2024-03-14","type":"pipeline","source":"PR Newswire","summary":"Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen's Off-the-shelf CAR-T Cellular Therapies - PR Newswire","headline":"Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen's Off-the-shelf CAR-T Cellular Ther","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxOZGhBTUtPejNSUTdmczhpSmRvb0ZxNWV5bWF0REF6UEtnajdWcWFkLUp6RVY5Q3RKYnhrVGNGcHR1LV9iQnJFUDNqVVVsVVdUR2FKdXpmc2czemJDdGdBUVRIMFBOX19oU3BGV242aFFldFF6SXljQTZ1ZUtldDZLbnFFWXFRcTdNeXVrTndLaVBSbzRZWWs1d1piVVZ0VGlCajNjZlV0ZmJRMm1qTUVZTGV6b3JvX0w4Y0FPTk9YOTNSOFNFeWYtOWFLWDFpdDRVRUpGMWJqM0Z4bzA2UTZJZ08waDdNMDNJUlhLZHgwYlFTOGlXZHBnQjRCWlhoQTJ5R3daSEtvNVRZeC1KMW0wS1d3Nk8tNjROQ1pJVUExMGhZdnlrZVNyU2ZmSkd1eVNwN2hNdjNJalVXTlQ4bWVCZGh3?oc=5","date":"2024-01-09","type":"pipeline","source":"PR Newswire","summary":"TORL BioTherapeutics Announces Appointment of Mark J. Alles as Chairman and Chief Executive Officer; Highlights Significant Progress of its Oncology Clinical Programs - PR Newswire","headline":"TORL BioTherapeutics Announces Appointment of Mark J. Alles as Chairman and Chief Executive Officer; Highlights Signific","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQRDMzbTJSVzQyYmgtZTVqUHd2dTlCUVdPRkJ3eXlZMTZtVEE4S20zbjdXTU96WkNTRlFUNG9CNHRQaTJjRnhyMzlHMWhTa0RMVkhaMFc1NHdPYlNmMnB6ZkRsMERtWExYaDJ2eENOMG9pNE5lRWttT1pFa2p4cnZlcGxWMHpTUzJ6Tm0xcjBBZzFjOHZCX1E?oc=5","date":"2023-10-30","type":"pipeline","source":"BioPharma Dive","summary":"Abingworth raises $356M to invest in late-stage drug development - BioPharma Dive","headline":"Abingworth raises $356M to invest in late-stage drug development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBEM0hScTlMMS1uMVpCNDRpUWFhM29OWVZ6Yzg0a012eTlpUUZwU2ZWMVdoRDNGQ1ZCWlFtR1VUc0dXemtYUE9aRU9sdGNaVXZYNVh6SmpQTjV0QlNyMllKOE1HWDR6SWtkSkZxb0N1Y3c4TlpQRTFiXzhFZ1FJZw?oc=5","date":"2023-05-11","type":"pipeline","source":"citybiz","summary":"Wugen Appoints Mark Alles As Chair - citybiz","headline":"Wugen Appoints Mark Alles As Chair","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPbDYzUTVuRUZCT0ROYTJnY1pnYmMtTEF2bjQyLU1oaXhOMERLeXROQzlVdkthc0ZSME4yclJGT214VnJFSlJsU1BuWUszT2lYX3JPaFU2U2EzcEVKRzljcGdPeDVhYXJzV3VfMU5FbExheldSWnpUUE95dWY0NExTU2dpMXlLWFVhMER0enJQQWNIVkw0SG1KbFMxdXhVX0p6eHlVTUswb2ZVSVQ5ODFfX1MzMFlpeXhLX3M2VWpWUmVmZmpnOFNqQndsUHh2eS1TT3Yw?oc=5","date":"2022-03-22","type":"pipeline","source":"ksdk.com","summary":"High-profile St. Louis startup relocates HQ to larger Cortex space where it could double its workforce - ksdk.com","headline":"High-profile St. Louis startup relocates HQ to larger Cortex space where it could double its workforce","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZUlRd2hPd1hPZEZhQnB2d1pCbU5MUEc3bFZlRDY2QjkwQkF6V21TZjZPR3RldzVOOTU5d3NQTFR2OXVhZDd0ck41SERsQzdUbWc1c05YZVNrcGZMQlAwaHAzbk03eEw2WHlHN0hsUEFRaFpiVXJnV3JsSmtaY1plaFFCUXpWZTFuUUlLTk9mSC1ERlFfSXhtY250VzI0UW85bXlEQ1c0NkVkZzNLZUl6cGMzVkc4UUliRE51ZWRqWjNZZw?oc=5","date":"2021-07-15","type":"pipeline","source":"Fierce Biotech","summary":"New CEO, check. $172M round, check. Wugen's off-the-shelf cell therapies are ready for takeoff - Fierce Biotech","headline":"New CEO, check. $172M round, check. Wugen's off-the-shelf cell therapies are ready for takeoff","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQbmJ3NnZDdXVpR1RsMVkxeUFZczk2X2p3NHZja2l0SWRmYXBxZV9RQW9jbjUzcUIwbHRCTElRd3FVNUFmbTF3UkwzOGtVYWNFYld1RUJ4aER2X1poVE8zc0tQMjJFYXF6UktkT0IzZkFFTTVxYi1hakR2Q21yUnd4MzlyTmNWYXlidXVxNnNEOTZaanRzb0N6c01HQVNza1V4VUJzeGJ0bng5ZXJ2VWRPcGRZdEJ1U3lidExiWU9xWkxjbGRESXZfUm5keWZHQ1hKdkc0UkVya0UtVlEyc0Mtam9n?oc=5","date":"2021-02-22","type":"pipeline","source":"BioSpace","summary":"Wugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company's Global NK and T cell Clinical Programs - BioSpace","headline":"Wugen Appoints Jan Davidson M.D., Ph.D., as Chief Medical Officer to Guide the Company's Global NK and T cell Clinical P","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":5,"phase_2":1},"enrichmentLevel":2,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}